Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$759.45M |
$3.35
+2.45%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$759.24M |
$1.20
+3.45%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$756.06M |
$7.86
+1.75%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$745.34M |
$5.38
+7.39%
|
|
EMBC
Embecta Corp.
Embecta operates as a medical device company focused on insulin injection devices, including pen needles, syringes, and safety products.
|
$735.16M |
$12.62
-7.11%
|
|
CRMD
CorMedix Inc.
DefenCath is an FDA-approved antimicrobial catheter-lock device marketed by CorMedix.
|
$720.36M |
$9.65
+2.66%
|
|
PACB
Pacific Biosciences of California, Inc.
PacBio directly manufactures diagnostic sequencing equipment (instruments) used in molecular diagnostics and research laboratories.
|
$717.89M |
$2.39
-9.13%
|
|
CTKB
Cytek Biosciences, Inc.
Cytek's instrument manufacturing includes flow cytometry diagnostic equipment, the core product line referenced in the article.
|
$712.45M |
$5.62
-3.52%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$712.37M |
$10.00
-4.40%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$711.08M |
$12.62
+2.27%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$710.77M |
$17.48
+0.95%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$707.14M |
$7.61
-3.79%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$704.35M |
$14.11
+6.25%
|
|
CLB
Core Laboratories N.V.
CLB provides laboratory testing and advisory services via proprietary tracers and reservoir analysis capabilities.
|
$701.06M |
$14.96
-0.50%
|
|
KE
Kimball Electronics, Inc.
KE's medical device and biometrics manufacturing capabilities are central to its strategy.
|
$698.95M |
$28.90
+1.16%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$695.93M |
$4.21
+1.57%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$693.53M |
$11.74
-0.42%
|
|
ORGO
Organogenesis Holdings Inc.
Core wound care device category covering Apligraf and Dermagraft, along with barrier products like PuraPly and FortiShield.
|
$687.57M |
$5.43
+2.84%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$675.84M |
$9.06
+2.20%
|
|
INNV
InnovAge Holding Corp.
InnovAge provides integrated care delivery and healthcare services at PACE centers and in-home settings, the core value proposition of their business.
|
$672.76M |
$4.96
-6.77%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$669.82M |
$13.26
-1.45%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$662.61M |
$9.45
+8.12%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$659.67M |
$8.21
+8.25%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$655.38M |
$9.63
+1.90%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$654.23M |
$10.63
+3.76%
|
|
OFIX
Orthofix Medical Inc.
Core product category covering orthopedic implants and surgical devices, including spinal hardware.
|
$637.44M |
$16.11
-0.12%
|
|
BVS
Bioventus Inc.
Bioventus designs and manufactures medical devices and biometrics solutions for musculoskeletal health.
|
$632.49M |
$7.65
-1.80%
|
|
NUTX
Nutex Health, Inc.
Nutex Health operates micro-hospitals and provides hospital services including acute inpatient care and emergency/observation services.
|
$627.81M |
$112.63
-5.52%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$627.00M |
$3.87
+23.48%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$623.88M |
$2.12
+1.19%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$620.28M |
$6.21
+1.97%
|
Showing page 16 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
